Urologic latency time during uroflow stop test with electromyography: an incontinence detector in rehabilitation after robotic radical prostatectomy.


Journal

European journal of physical and rehabilitation medicine
ISSN: 1973-9095
Titre abrégé: Eur J Phys Rehabil Med
Pays: Italy
ID NLM: 101465662

Informations de publication

Date de publication:
Feb 2023
Historique:
pubmed: 29 10 2022
medline: 7 3 2023
entrez: 28 10 2022
Statut: ppublish

Résumé

Stress urinary incontinence (UI) is the most common presentation following robot-assisted radical prostatectomy (RARP), but a postoperative non-invasive and objective test is still lacking. To assess pelvic floor integrity after RARP, we recently proposed Uroflow Stop Test (UST) with surface electromyography (EMG). Here we provide two new clinical parameters: the neurologic latency time (NLT) and the urologic latency time (ULT) derived from UST-EMG Test. Principal outcome was to evaluate their variation during one year follow-up and ULT ability to predict post-RARP UI. Observational and longitudinal study. Interdivisional Urology Clinic (Perugia-Terni, Italy). Patients with prostate cancer treated with a full nerve-sparing RARP who underwent postoperative pelvic floor muscles training (PFMT): a diurnal functional home program and a weekly hospital program with the use of biofeedback, between 1 and 3 months postoperatively. All patients consecutively performed a UST-EMG test at one, three, six, and twelve months after surgery. At each follow-up visit we collected NLT values, ULT values, 5-item 26-Expanded Prostate Cancer Index (EPIC), Incontinence Developed on Incontinence Questionnaire (ICIQ-UI) Short Form and International Prostate Symptom Score (IPSS). We analysed statistically significant differences in NLT and ULT between continent and incontinent patients and we evaluate the diagnostic ability of 1-month post-surgery ULT value to diagnose the presence of postoperative UI. Sixty patients were enrolled. The mean time to PFMT was 31.08 (range: 30-35) days. Overall IPSS, NLT and ULT had similar trends: progressive decrease until the six months after surgery (1-month vs. 3 months vs. 6 months, P<0.05) to plateau thereafter. When considering the two group of patients, IPSS and NLT were significantly higher in the incontinent group only one month after surgery, while ULT became similar between the two groups at 6 months after surgery. The best cut-off of 1-month ULT values that maximized the Youden function at 12-months resulted 3.13 second. NLT and ULT may respectively account for the nerve and the urethral closure system integrity post-RARP. In the first month after RARP, both NLT and ULT differs between incontinent vs. continent patients. NLT become similar between two group after one month, confirming the recovery from neuropraxia, but ULT remains statistically significant different until 3 months postoperatively. The value of 1-month ULT resulted a valid tool to predict incontinence status at 12 months. ULT and NLT may be also useful tools to monitor the continence progressive recovery after RARP and they may help rehabilitation specialists to evaluate the ongoing results during postoperative follow-up.

Sections du résumé

BACKGROUND BACKGROUND
Stress urinary incontinence (UI) is the most common presentation following robot-assisted radical prostatectomy (RARP), but a postoperative non-invasive and objective test is still lacking. To assess pelvic floor integrity after RARP, we recently proposed Uroflow Stop Test (UST) with surface electromyography (EMG).
AIM OBJECTIVE
Here we provide two new clinical parameters: the neurologic latency time (NLT) and the urologic latency time (ULT) derived from UST-EMG Test. Principal outcome was to evaluate their variation during one year follow-up and ULT ability to predict post-RARP UI.
DESIGN METHODS
Observational and longitudinal study.
SETTING METHODS
Interdivisional Urology Clinic (Perugia-Terni, Italy).
POPULATION METHODS
Patients with prostate cancer treated with a full nerve-sparing RARP who underwent postoperative pelvic floor muscles training (PFMT): a diurnal functional home program and a weekly hospital program with the use of biofeedback, between 1 and 3 months postoperatively.
METHODS METHODS
All patients consecutively performed a UST-EMG test at one, three, six, and twelve months after surgery. At each follow-up visit we collected NLT values, ULT values, 5-item 26-Expanded Prostate Cancer Index (EPIC), Incontinence Developed on Incontinence Questionnaire (ICIQ-UI) Short Form and International Prostate Symptom Score (IPSS). We analysed statistically significant differences in NLT and ULT between continent and incontinent patients and we evaluate the diagnostic ability of 1-month post-surgery ULT value to diagnose the presence of postoperative UI.
RESULTS RESULTS
Sixty patients were enrolled. The mean time to PFMT was 31.08 (range: 30-35) days. Overall IPSS, NLT and ULT had similar trends: progressive decrease until the six months after surgery (1-month vs. 3 months vs. 6 months, P<0.05) to plateau thereafter. When considering the two group of patients, IPSS and NLT were significantly higher in the incontinent group only one month after surgery, while ULT became similar between the two groups at 6 months after surgery. The best cut-off of 1-month ULT values that maximized the Youden function at 12-months resulted 3.13 second.
CONCLUSIONS CONCLUSIONS
NLT and ULT may respectively account for the nerve and the urethral closure system integrity post-RARP. In the first month after RARP, both NLT and ULT differs between incontinent vs. continent patients. NLT become similar between two group after one month, confirming the recovery from neuropraxia, but ULT remains statistically significant different until 3 months postoperatively. The value of 1-month ULT resulted a valid tool to predict incontinence status at 12 months.
CLINICAL REHABILITATION IMPACT CONCLUSIONS
ULT and NLT may be also useful tools to monitor the continence progressive recovery after RARP and they may help rehabilitation specialists to evaluate the ongoing results during postoperative follow-up.

Identifiants

pubmed: 36305651
pii: S1973-9087.22.07365-8
doi: 10.23736/S1973-9087.22.07365-8
pmc: PMC10035442
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-102

Références

Neurourol Urodyn. 2015 Jan;34(1):60-4
pubmed: 23983137
Int J Nurs Stud. 2016 Aug;60:99-111
pubmed: 27297372
Int Urol Nephrol. 2019 Apr;51(4):609-615
pubmed: 30798475
BMC Urol. 2019 Nov 15;19(1):116
pubmed: 31729959
Minerva Urol Nefrol. 2020 Oct;72(5):555-562
pubmed: 32432436
J Urol. 2007 Jul;178(1):208-11
pubmed: 17499806
Int Urogynecol J. 2017 Jan;28(1):95-100
pubmed: 27379890
J Anat. 2018 Oct;233(4):447-459
pubmed: 30051458
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
Sci Rep. 2018 May 8;8(1):7111
pubmed: 29740090
Neurourol Urodyn. 2018 Sep;37(7):2053-2087
pubmed: 29687914
Eur Urol. 2007 Mar;51(3):629-39
pubmed: 17137708
Neurourol Urodyn. 2016 Nov;35(8):1034-1039
pubmed: 26352154
Eur Urol. 2009 Jan;55(1):148-54
pubmed: 18835086
J Urol. 2011 Mar;185(3):869-75
pubmed: 21239008
J Robot Surg. 2016 Dec;10(4):331-335
pubmed: 27160677
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001843
pubmed: 17443512
J Gerontol. 1994 Jul;49(4):P179-89
pubmed: 8014399
Eur Urol. 2012 Sep;62(3):368-81
pubmed: 22763081
J Electromyogr Kinesiol. 2000 Oct;10(5):361-74
pubmed: 11018445
BJU Int. 2012 Sep;110(6):875-83
pubmed: 22260307
Eur Urol Focus. 2019 Sep;5(5):823-830
pubmed: 29759661
Radiol Med. 2019 Oct;124(10):946-954
pubmed: 31197647
J Endourol. 2012 Dec;26(12):1546-52
pubmed: 23230868
Semin Oncol Nurs. 2020 Aug;36(4):151050
pubmed: 32674975
J Endourol. 2017 Jan;31(1):32-37
pubmed: 27824258
Exp Aging Res. 1998 Oct-Dec;24(4):359-85
pubmed: 9783155
Health Qual Life Outcomes. 2019 Aug 29;17(1):147
pubmed: 31464649
Urology. 2015 Oct;86(4):766-71
pubmed: 26254170
Eur Urol. 2016 Apr;69(4):584-589
pubmed: 26277303

Auteurs

Andrea Boni (A)

Department of Surgical and Biomedical Sciences, Interdivisional Urology Clinic (Perugia-Terni), University Hospital of Perugia, Perugia, Italy.

Fabrizio Gervasoni (F)

Unit of Rehabilitation, Luigi Sacco University Hospital, A.S.S.T. Fatebenefratelli-Sacco, Milan, Italy.

Antonella Lomauro (A)

Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy - antonella.lomauro@polimi.it.

Michele Del Zingaro (M)

Department of Surgical and Biomedical Sciences, Interdivisional Urology Clinic (Perugia-Terni), University Hospital of Perugia, Perugia, Italy.

Giuseppe Maiolino (G)

Department of Surgical and Biomedical Sciences, Interdivisional Urology Clinic (Perugia-Terni), University Hospital of Perugia, Perugia, Italy.

Chiara Galletti (C)

Department of Psychiatry, Santa Maria University Hospital, Terni, Italy.

Vincenzo Ricci (V)

Unit of Rehabilitation, Luigi Sacco University Hospital, A.S.S.T. Fatebenefratelli-Sacco, Milan, Italy.

Ettore Mearini (E)

Department of Surgical and Biomedical Sciences, Interdivisional Urology Clinic (Perugia-Terni), University Hospital of Perugia, Perugia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH